Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Xuping Xie, Jing Zou, Camila R. Fontes-Garfias, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

SARS-CoV-2 variants, spike mutations and immune escape
William T. Harvey, Alessandro M. Carabelli, Ben Jackson, et al.
Nature Reviews Microbiology (2021) Vol. 19, Iss. 7, pp. 409-424
Open Access | Times Cited: 3370
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan, Noam Barda, Eldad Kepten, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 15, pp. 1412-1423
Open Access | Times Cited: 2543
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang, Fabian Schmidt, Yiska Weisblum, et al.
Nature (2021) Vol. 592, Iss. 7855, pp. 616-622
Open Access | Times Cited: 1438
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
BMJ (2021), pp. n1088-n1088
Open Access | Times Cited: 1202
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, et al.
The Lancet (2021) Vol. 397, Iss. 10282, pp. 1351-1362
Open Access | Times Cited: 624
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Alexander Muik, Ann-Kathrin Wallisch, Bianca Sänger, et al.
Science (2021) Vol. 371, Iss. 6534, pp. 1152-1153
Open Access | Times Cited: 542
SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients
Daryl Geers, Marc C. Shamier, Susanne Bogers, et al.
Science Immunology (2021) Vol. 6, Iss. 59
Open Access | Times Cited: 520
Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival
Stefania Dispinseri, Massimiliano Secchi, Maria Franca Pirillo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 352
Covid‐19 vaccines and variants of concern: A review
Ikbel Hadj Hassine
Reviews in Medical Virology (2021) Vol. 32, Iss. 4
Open Access | Times Cited: 313
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study
Mark S. Graham, Carole H. Sudre, Anna May, et al.
The Lancet Public Health (2021) Vol. 6, Iss. 5, pp. e335-e345
Open Access | Times Cited: 309
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
Maria Teresa Mascellino, Federica Di Timoteo, Massimiliano De Angelis, et al.
Infection and Drug Resistance (2021) Vol. Volume 14, pp. 3459-3476
Open Access | Times Cited: 241
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
John P. Moore, Paul A. Offit
JAMA (2021) Vol. 325, Iss. 9, pp. 821-821
Closed Access | Times Cited: 236
Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
Victoria Rotshild, Bruria Hirsh Raccah, Ian Miskin, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 217
Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant
Gard Nelson, Oleksandr Buzko, Patricia Spilman, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 210
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Emily H. Pilkington, Estelle J. A. Suys, Natalie L. Trevaskis, et al.
Acta Biomaterialia (2021) Vol. 131, pp. 16-40
Open Access | Times Cited: 196
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 195
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
Alona Kuzmina, Yara Khalaila, Olga Voloshin, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 522-528.e2
Open Access | Times Cited: 192
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang, Fabian Schmidt, Yiska Weisblum, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 183
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
Gary R. McLean, Jeremy P. Kamil, Benhur Lee, et al.
mBio (2022) Vol. 13, Iss. 2
Open Access | Times Cited: 174
Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
Lianlian Bian, Fan Gao, Jialu Zhang, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 4, pp. 365-373
Open Access | Times Cited: 168
Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
Julian W. Tang, Oliver T. R. Toovey, Kirsty N. Harvey, et al.
Journal of Infection (2021) Vol. 82, Iss. 4, pp. e8-e10
Open Access | Times Cited: 167
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 166
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Thomas P. Peacock, Rebekah Penrice-Randal, Julian A. Hiscox, et al.
Journal of General Virology (2021) Vol. 102, Iss. 4
Open Access | Times Cited: 166
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
Chris R. Triggle, Devendra Bansal, Hong Ding, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 165
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Oren K. Fix, Emily A. Blumberg, Kyong‐Mi Chang, et al.
Hepatology (2021) Vol. 74, Iss. 2, pp. 1049-1064
Open Access | Times Cited: 151
Page 1 - Next Page

Scroll to top